Cart
sales@molnova.com
Enerisant HCl
CAS No. 1152749-07-9
Enerisant HCl( —— )
Catalog No. M36346 CAS No. 1152749-07-9
Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 216 | In Stock |
|
| 10MG | 347 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 797 | In Stock |
|
| 100MG | 1070 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEnerisant HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionEnerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
-
DescriptionEnerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
RecptorP450 | Histamine Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1152749-07-9
-
Formula Weight434.96
-
Molecular FormulaC22H31ClN4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(=O)(C1=CN(N=C1)C2=CC=C(OCCCN3[C@H](C)CCC3)C=C2)N4CCOCC4.Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
NSC 207895
NSC 207895 suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase.
-
Dafadine-A
Dafadine-A is an analog of dafadine and a novel inhibitor of DAF-9 cytochrome P450 in the nematode Caenorhabditis elegans.
-
Ginsenoside F1
Ginsenoside F1,an enzymatically modified derivative of ginsenoside Rg1, protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression.
